RIGEL PHARMACEUTICALS INC

For the period ended Dec 31, 2023. Filed Mar 5, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 5, 2024

RIGL$42.05+6.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Statements of Operations

(In thousands, except per share amounts)


	Year Ended December 31,
	2023		2022		2021
Revenues:
Product sales, net		$104,294		$76,718		$63,010
Contract revenues from collaborations		11,488		39,024		75,726
Government contracts		1,100		4,500		10,500
Total revenues		116,882		120,242		149,236
Costs and expenses:
Cost of product sales		7,110		1,749		1,083
Research and development		24,522		60,272		65,237
Selling, general and administrative		105,741		112,451		91,891
Restructuring charges		—		1,320		3,521
Total costs and expenses		137,373		175,792		161,732
Loss from operations		(20,491)		(55,550)		(12,496)
Interest income		2,272		684		47
Interest expense		(6,872)		(3,707)		(4,860)
Loss before income taxes		(25,091)		(58,573)		(17,309)
Provision for income taxes		—		—		605
Net loss		$(25,091)		$(58,573)		$(17,914)

Net loss per share, basic and diluted		$(0.14)		$(0.34)		$(0.11)
Weighted average shares used in computing net loss per share, basic and diluted		174,017		172,406		170,492

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.